Julie Jones is the founder and CEO of BioValeo, a New Zealand-based Contract Research Organization (CRO) that provides services to companies developing precision or personalized medicine interventions.

As medicine advances, treatments become more specific and tailored to the individual patient. Rather than bundling patients according to a high-level disease category, next-generation treatments provide targeted interventions based on a specific set of characteristics, for example through their genetic or other biomarkers. With this increased /"Precision/" or /"Personalization/

Please take the opportunity to connect and share this video with your friends and family if you find it helpful.